Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SwissHandSpasm: Xeomin for Focal Hand Dystonia
NCT03977493Phase 3Recruiting
- Start
- Feb 2018
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Focal hand dystonia (FHD) comparing Xeomin® with Placebo concentrate (2 arms). Primary endpoint: Evaluation of the efficacy of IncobotulinumtoxinA on focal hand dystonia (FHD) at 6 weeks. Started Feb 2018; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
Focal hand dystonia (FHD)
Beyond the preview
Go deeper on NCT03977493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977493.